English
SpanishTrusted Resources: Evidence & Education
Scientific literature and patient education texts
Immunotherapy for Graves’ Ophthalmopathy
source: Current Opinion in Endocrinology, Diabetes, and Obesity
year: 2014
authors: Salvi M
summary/abstract:Purpose of Review:
In recent years, immunosuppressive therapy, as an alternative to corticosteroids, has been proposed as novel agents which target the various antigens involved in the pathogenesis of Graves’ ophthalmopathy. Although the lack of randomized and controlled studies suggests caution in generalizing results, some data show interesting results.
Recent Findings:
Potential targets for immune therapy in Graves’ ophthalmopathy are the antigens expressed on the target organ of inflammation, namely the receptor and the insulin growth factor -1 receptor on fibroblasts, inflammatory cytokines, and B and T cells. The most promising results are observed with small thyroid stimulating hormone receptor molecules interacting with the receptor on thyrocytes and fibroblasts and with the anti-IGF-1 receptor antibody teprotumumab. A recent open study with tocilizumab, an anti-soluble interleukin-6 receptor, has shown inactivation of Graves’ ophthalmopathy. Consistent reports on the efficacy of rituximab will have to be confirmed by randomized controlled trials, which are now in progress.
Summary:
Current clinical practice for Graves’ ophthalmopathy will greatly benefit from the availability of immunosuppressors that act as disease-modifying drugs, as compared to steroids, the current standard treatment for Graves’ ophthalmopathy. Rituximab seems to be a good candidate, as preliminary results from ongoing randomized trials suggest good efficacy with a relative well tolerated profile.
DOI: 10.1097/MED.0000000000000097
read more
myBinderRelated Content
-
Shannath Louise Merbs, MD, PhD, FACSShannath Louise Merbs is a fellowship-tr...
-
Recent Developments in Graves’ OphthalmopathyRecent Developments in Graves' ophthalmo...
-
Management of Patients With Graves’ Orbitopathy: Initial Assessment, Management Outside Specialised Centres and Re...Graves' orbitopathy (GO) is uncommon, bu...
-
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
-
Mortality in Graves’ Orbitopathy is Increased and Influenced By Gender, Age and Pre-Existing Morbidity: A Nati...Introduction: It is unclear whether the...
-
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
-
Mario Salvi, MDDr. Mario Salvi is a specialist in endoc...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
